The Ministry of Health and Medical Education (MOHME) will purchase 20,000 vials of Haemate P in 500 IU vials in the first year of launch, administering it in four treatment centers throughout Iran. CSL Behring and the MOHME plan to collaborate on von Willebrand disease (VWD) testing, detection and treatment projects to benefit Iranian families impacted by VWD.
CSL Behring is reported to be the first and only company to bring VWD treatment to Iran, where the incidence of the condition is reportedly up to 10 times higher than in other areas of the world.
Haemate P is indicated for the treatment of VWD, a serious, hereditary, and sometimes life-threatening condition caused by a deficiency or abnormality of the von Willebrand factor, a protein in the blood that is necessary for normal blood clotting.
Paul Perreault, executive vice president of worldwide commercial operations at CSL Behring, said: “By introducing Haemate P into Iran, CSL Behring is offering many Type III VWD patients a safe, effective alternative to treating a health condition that can have a significant impact on a patient’s quality of life, and that, at times, can even be life-threatening.”